PL2968483T3 - Podskórne podawanie adamts13 - Google Patents

Podskórne podawanie adamts13

Info

Publication number
PL2968483T3
PL2968483T3 PL14719469T PL14719469T PL2968483T3 PL 2968483 T3 PL2968483 T3 PL 2968483T3 PL 14719469 T PL14719469 T PL 14719469T PL 14719469 T PL14719469 T PL 14719469T PL 2968483 T3 PL2968483 T3 PL 2968483T3
Authority
PL
Poland
Prior art keywords
adamts13
subcutaneous administration
subcutaneous
administration
Prior art date
Application number
PL14719469T
Other languages
English (en)
Inventor
Alexandra Nathalie Kopic
Werner Hoellriegl
Barbara Plaimauer
Hanspeter Rottensteiner
Eva-Maria Muchitsch
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of PL2968483T3 publication Critical patent/PL2968483T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
PL14719469T 2013-03-15 2014-03-13 Podskórne podawanie adamts13 PL2968483T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361794659P 2013-03-15 2013-03-15
PCT/US2014/026747 WO2014151968A1 (en) 2013-03-15 2014-03-13 Subcutaneous administration of adamts13
EP14719469.0A EP2968483B1 (en) 2013-03-15 2014-03-13 Subcutaneous administration of adamts13

Publications (1)

Publication Number Publication Date
PL2968483T3 true PL2968483T3 (pl) 2022-04-04

Family

ID=50549463

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14719469T PL2968483T3 (pl) 2013-03-15 2014-03-13 Podskórne podawanie adamts13

Country Status (19)

Country Link
US (4) US9611467B2 (pl)
EP (2) EP3960196A1 (pl)
JP (4) JP6484216B2 (pl)
KR (5) KR102218489B1 (pl)
CN (2) CN114259558A (pl)
AU (5) AU2013203062C1 (pl)
BR (1) BR112015023542A8 (pl)
CA (1) CA2905058A1 (pl)
DK (1) DK2968483T3 (pl)
EA (2) EA201992832A1 (pl)
ES (1) ES2906550T3 (pl)
HK (1) HK1220131A1 (pl)
IL (3) IL241305B (pl)
MX (2) MX2015012783A (pl)
PL (1) PL2968483T3 (pl)
PT (1) PT2968483T (pl)
SG (3) SG11201507271QA (pl)
TW (4) TWI740207B (pl)
WO (1) WO2014151968A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203062C1 (en) 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
GB201510870D0 (en) * 2015-05-26 2015-08-05 Baxalta Inc And Katholieke Universiteit Leuven And Baxalta Gmbh Treatment of infarction
MX2019001255A (es) 2016-08-04 2019-05-20 Baxalta Inc Uso de una desintegrina y metaloproteinasa con motivo tipo 1 de trombospondina, miembro-13 (adamts13) para tratar, mejorar y/o prevenir crisis vaso-oclusiva en enfermedad de celulas falciformes, lesion pulmonar aguda y/o sindrome de insuficiencia respiratoria aguda.
WO2020214033A1 (en) * 2019-04-17 2020-10-22 Erasmus University Medical Center Rotterdam Papain-like cysteine peptidase medicaments and uses thereof
KR20230005192A (ko) 2020-04-02 2023-01-09 다케다 야쿠힌 고교 가부시키가이샤 Adamts13 변이체, 조성물 및 그의 용도
WO2021234458A1 (en) 2020-05-22 2021-11-25 Takeda Pharmaceutical Company Limited Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease
US20230405096A1 (en) * 2020-11-18 2023-12-21 Green Cross Corporation Adamts13 variant having increased escaping rate or activity against autoantibody
GB202102208D0 (en) * 2021-02-17 2021-03-31 Univ Manchester Adamts13 variant
WO2024151093A1 (ko) * 2023-01-11 2024-07-18 주식회사 녹십자 혈전성 질환의 예방 또는 치료를 위한 신규한 액상 제형물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113010A0 (en) 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
WO2003016492A2 (en) * 2001-08-16 2003-02-27 The Regents Of The University Of Michigan Adamts13 genes and proteins and variants, and uses thereof
US7763430B2 (en) * 2003-04-22 2010-07-27 Baxter International Inc. Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
ES2382104T3 (es) 2005-06-17 2012-06-05 Baxter International Inc. Composiciones con actividad trombolítica que comprenden ADAMTS13
JP2009539757A (ja) * 2006-06-16 2009-11-19 バクスター・インターナショナル・インコーポレイテッド 血栓溶解活性を有するａｄａｍｔｓ１３含有組成物
EP2288377A1 (en) 2008-05-12 2011-03-02 Immune Disease Institute Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
AU2010284977A1 (en) * 2009-08-20 2012-03-29 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
JP5819303B2 (ja) * 2009-09-21 2015-11-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 安定化された液体および凍結乾燥ａｄａｍｔｓ１３製剤
TWI670073B (zh) 2010-07-08 2019-09-01 美商巴克斯歐塔公司 在細胞培養物中生產重組高分子量ｖＷＦ的方法
AU2013203062C1 (en) 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13

Also Published As

Publication number Publication date
WO2014151968A1 (en) 2014-09-25
TWI690326B (zh) 2020-04-11
AU2013203062C1 (en) 2018-06-28
IL241305A0 (en) 2015-11-30
US11779635B2 (en) 2023-10-10
KR102513872B1 (ko) 2023-03-27
US20200101144A1 (en) 2020-04-02
IL290486A (en) 2022-04-01
TW202017591A (zh) 2020-05-16
MX2021002513A (es) 2021-04-28
EA201591758A1 (ru) 2016-03-31
DK2968483T3 (da) 2022-02-14
JP6484216B2 (ja) 2019-03-13
AU2020202738A1 (en) 2020-05-14
IL290486B2 (en) 2023-08-01
TW201513881A (zh) 2015-04-16
TWI740207B (zh) 2021-09-21
EA201992832A1 (ru) 2020-05-31
NZ749570A (en) 2020-11-27
US20140271611A1 (en) 2014-09-18
US9611467B2 (en) 2017-04-04
KR102102087B1 (ko) 2020-04-20
US20170224785A1 (en) 2017-08-10
BR112015023542A8 (pt) 2019-12-03
JP2023071821A (ja) 2023-05-23
US10413600B2 (en) 2019-09-17
JP7238088B2 (ja) 2023-03-13
KR102218489B1 (ko) 2021-02-22
PT2968483T (pt) 2022-02-23
CA2905058A1 (en) 2014-09-25
NZ712440A (en) 2020-11-27
TW202313664A (zh) 2023-04-01
SG10201707074TA (en) 2017-10-30
AU2022211908A1 (en) 2022-09-01
IL290486B1 (en) 2023-04-01
JP2022027991A (ja) 2022-02-14
HK1220131A1 (zh) 2017-04-28
TW202138003A (zh) 2021-10-16
AU2013203062A1 (en) 2014-10-02
TWI786563B (zh) 2022-12-11
KR20190022926A (ko) 2019-03-06
IL241305B (en) 2020-04-30
KR20200041394A (ko) 2020-04-21
EA201591758A8 (ru) 2017-03-31
KR102365936B1 (ko) 2022-02-23
KR20220027266A (ko) 2022-03-07
EP2968483A1 (en) 2016-01-20
WO2014151968A8 (en) 2015-10-15
AU2016231547B2 (en) 2018-03-15
AU2016231547A1 (en) 2016-10-06
JP6998333B2 (ja) 2022-02-10
JP2016517421A (ja) 2016-06-16
EA034546B1 (ru) 2020-02-19
MX2015012783A (es) 2016-04-28
IL273365B (en) 2022-05-01
KR20210021107A (ko) 2021-02-24
CN114259558A (zh) 2022-04-01
US20220080032A1 (en) 2022-03-17
SG10202001227QA (en) 2020-03-30
AU2013203062B2 (en) 2016-06-23
US11185575B2 (en) 2021-11-30
AU2018203665A1 (en) 2018-06-14
JP2019142850A (ja) 2019-08-29
EP3960196A1 (en) 2022-03-02
NZ751610A (en) 2020-11-27
ES2906550T3 (es) 2022-04-19
IL273365A (en) 2020-05-31
EP2968483B1 (en) 2021-12-01
SG11201507271QA (en) 2015-10-29
AU2022211908B2 (en) 2023-11-30
CN105407912A (zh) 2016-03-16
BR112015023542A2 (pt) 2017-07-18
AU2020202738B2 (en) 2022-06-09
AU2018203665B2 (en) 2020-01-30
KR20160016756A (ko) 2016-02-15

Similar Documents

Publication Publication Date Title
IL287516A (en) Medicinal uses of empagliflozin
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
IL290486A (en) Subcutaneous administration of adamts13
IL244259A0 (en) Insertion of medical devices
HK1213818A1 (zh) 依帕列淨的治療用途
EP2968894A4 (en) MEDICAL CONNECTION
AU357213S (en) Patient interface
PT2922514T (pt) Interface de paciente birradial
AU353287S (en) Patient interface
AU353289S (en) Patient interface
EP3459587C0 (en) NEEDLELESS CONNECTOR
GB201307385D0 (en) Syringes
ZA201506252B (en) Syringe
LT2981271T (lt) Empagliflozino terapinis panaudojimas
PL2950876T3 (pl) Ulepszone złącze do użytku medycznego
EP2971029A4 (en) PREPARATION OF MALTOOLIGOSACCHARIDES
GB201321078D0 (en) Syringe assemblies
GB201408677D0 (en) Syringes
EP2978473A4 (en) AUTOMATIC RETRACTABLE SYRINGE
ZA201405476B (en) Anthelmintic medicament
GB201320786D0 (en) Medicament
AU354914S (en) Patient interface
AU354913S (en) Patient interface
AU353572S (en) Patient interface
GB201310897D0 (en) Angloplasty catheter set